Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FACTS 001: Tenofovir Gel for HIV and HSV-2 Prevention in Women
NCT01386294Phase 3Completed
- Sponsor
- CONRAD
- Start
- Oct 2011
- Primary completion
- Aug 2014
- Modality
- Implantable Devices, Transdermal Patches, Hydrogel Systems
- Countries
- 1
01
Overview
A Phase 3 trial of tenofovir gel in human immunodeficiency virus infection (HIV), Herpes Simplex Virus Type 2 Infection (HSV-2), sponsored by CONRAD. Started Oct 2011; status: completed.
02
Drugs
tenofovir gel
03
Conditions
human immunodeficiency virus infection (HIV)Herpes Simplex Virus Type 2 Infection (HSV-2)
Beyond the preview
Go deeper on NCT01386294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01386294.